. 2020 Aug 3;19:121. doi: 10.1186/s12933-020-01103-7

Table 1.

Clinical and biochemical parameters for control subjects and diabetic patients, according to quartile of ANGPTL8 levels

Characteristics	Control (ANGPTL8, pg/mL)				p value	Diabetes (ANGPTL8, pg/mL)				p value
Characteristics	Q1 (< 372.15)	Q2 (372.15–537.58)	Q3 (537.59–74.09)	Q4 (> 746.09)	p value	Q1 (< 347.15)	Q2 (347.15–534.23)	Q3 (534.24–810.50)	Q4 (> 810.50)	p value
N	192	193	192	192		192	193	192	192
ANGPTL8 (pg/ml)	261.28 (188.24–317.25)	432.03 (403.26–476.68)	623.40 (573.62–690.53)	959.43 (850.77–1143.01)	< 0.001	256.45 (189.45–300.93)	462.97 (406.66–496.93)	642.52 (586.97–729.70)	1009.54 (893.07–1268.33)	< 0.001
Age (years)	54.44 $\pm$ 9.03	56.97 $\pm$ 8.75	59.54 $\pm$ 8.91	64.87 $\pm$ 9.82	< 0.001	59.14 $\pm$ 9.56	58.30 $\pm$ 9.37	61.33 $\pm$ 9.21	63.57 $\pm$ 9.16	< 0.001
Male (%)	47 (24.5)	59 (30.6)	68 (35.4)	92 (47.9)	< 0.001	40 (20.8)	59 (30.6)	68 (35.4)	99 (51.6)	< 0.001
BMI (kg/m²)	23.39 $\pm$ 3.16	23.05 $\pm$ 3.03	23.35 $\pm$ 2.93	23.71 $\pm$ 3.21	0.24	24.37 $\pm$ 3.50	24.79 $\pm$ 3.44	24.10 $\pm$ 3.23	23.62 $\pm$ 3.67	0.009
WHR	0.84 (0.80–0.88)	0.85 (0.81–0.89)	0.85 (0.81–0.90)	0.87 (0.83–0.90)	0.005	0.88 (0.85–0.91)	0.88 (0.84–0.93)	0.88 (0.84–0.92)	0.88 (0.84–0.91)	0.53
SBP	139 (127–156)	145 (129–162)	146 (130–164)	151 (135–168)	< 0.001	150 (136–168)	149 (135–166)	155 (138–173)	154 (137–173)	0.33
HbA1c (%)	5.50 (5.30–5.80)	5.50 (5.30–5.70)	5.60 (5.40–5.80)	5.60 (5.40–5.90)	0.003	6.50 (5.80–7.70)	6.50 (5.85–8.15)	6.55 (5.90–8.15)	6.40 (5.73–7.80)	0.62
FPG (mmol/L)	5.04 (4.75–5.34)	5.02 (4.77–5.28)	5.00 (4.72–5.26)	5.06 (4.80–5.31)	0.39	7.18 (5.95–8.13)	7.26 (6.19–9.02)	7.37 (6.05–8.98)	7.35 (5.98–8.66)	0.38
2 h PG (mmol/L)	5.72 (4.92–6.42)	5.83 (5.01–6.56)	5.72 (4.91–6.44)	5.84 (5.20–6.63)	0.18	11.38 (7.93–13.72)	12.17 (7.77–15.70)	12.12 (8.31–14.38)	12.06 (9.24–15.74)	0.09
Fasting insulin (pmol/mL)	5.00 (3.50–7.08)	4.80 (3.20–6.90)	4.80 (3.40–7.10)	4.80 (3.40–7.00)	0.58	6.80 (4.30–12.50)	7.10 (4.25–10.95)	6.85 (4.40–10.45)	6.15 (3.63–11.18)	0.48
HOMA-IR	1.19 (0.77–1.62)	1.09 (0.70–1.52)	1.06 (0.74–1.59)	1.06 (0.77–1.59)	0.72	2.24 (1.41–4.04)	2.39 (1.33–4.13)	2.42 (1.34–3.98)	2.17 (1.15–4.00)	0.59
HOMA- $β$ (%)	66.221 (45.56–89.32)	61.76 (44.59–91.01)	70.91 (44.32–100.00)	59.98 (42.72–84.54)	0.20	41.76 (23.60–73.88)	38.76 (18.13–73.84)	36.27 (22.39–63.55)	36.14(17.70–65.55)	0.31
Fasting HDL (mmol/L)	1.37 (1.14–1.60)	1.38 (1.17–1.60)	1.36 (1.15–1.61)	1.34 (1.13–1.61)	0.94	1.44 (1.24–1.70)	1.35 (1.17–1.61)	1.35 (1.16–1.58)	1.32 (1.11–1.62)	0.03
Fasting LDL (mmol/L)	2.43 (2.06–2.96)	2.58 (2.11–3.06)	2.59 (2.10–3.06)	2.62 (2.17–3.04)	0.25	2.93 (2.37–3.64)	2.97 (2.36–3.54)	3.03 (2.42–3.61)	2.83 (2.25–3.50)	0.20
Fasting TG (mmol/L)	1.19 (0.87–1.63)	1.18 (0.90–1.73)	1.16 (0.86–1.74)	1.23 (0.89–1.74)	0.45	1.46 (1.04–2.17)	1.46 (0.95–2.10)	1.49 (1.07–2.08)	1.49 (1.00–2.55)	0.67
Cholesterol (mmol/L)	4.58 (3.92–5.24)	4.67 (4.15–5.30)	4.61 (4.08–5.37)	4.86 (4.19–5.44)	0.10	5.16 (4.57–6.16)	5.13 (4.47–5.85)	5.14 (4.48–5.90)	5.10 (4.38–5.98)	0.78
ALT (U/L)	13 (10–18)	13 (10–17)	14 (11–18)	14 (10–18)	0.48	12 (9–18)	13 (10–19)	14 (10–21)	14 (10–22)	0.05
AST (U/L)	21 (17–25)	23 (19–26)	23 (20–27)	23 (20–28)	< 0.001	20 (17–26)	21 (17–26)	21 (17–28)	23 (18–31)	0.007
eGFR (mL/min/1.73 m²)	119.54 (107.40–134.39)	119.41 (105.77–130.13)	116.88 (101.22–128.33)	108.12 (92.58–122.90)	< 0.001	113.51 (100.39–120.63)	111.67 (100.23–120.27)	108.58 (97.16–119.44)	106.71 (90.35–118.79)	0.008
Creatinine (μmol/L)	58.10 (52.33–64.85)	58.50 (53.40–64.45)	61.05 (55.43–66.83)	65.45 (57.18–72.98)	< 0.001	60.80 (55.90–65.48)	62.00 (56.90–68.05)	63.10 (58.13–69.05)	66.60 (59.85–74.68)	< 0.001
Currently smoking	19 (10.2)	36 (18.8)	20 (10.6)	43 (23.0)	0.001	15 (8.7)	20 (10.9)	29 (16.1)	50 (26.5)	< 0.001
Hypertension	96 (50.0)	119 (61.7)	122 (63.5)	141 (73.4)	< 0.001	143 (74.5)	142 (73.6)	146 (76)	152 (79.2)	0.59
Hyperlipidaemia	62 (32.2)	69 (35.8)	72 (37.0)	85 (44.3)	0.10	113 (58.9)	105 (54.4)	93 (48.4)	124 (64.6)	0.01

BMI body-mass index, WHR waist hip rate, SBP systolic blood pressure, HbA1c glycated haemoglobin A1c, FPG fasting plasma glucose, 2 h PG 2 h plasma glucose concentration, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-β, homeostasis model assessment of β cell function, HDL high density lipoprotein, LDL low density lipoprotein, TG triglycerides, ALT alanine transaminase, AST aspartate aminotransferase, Egfr glomerular filtration rate